

## **SUPPLEMENTARY INFORMATION**

### **Title**


Osteopontin expression in small airway epithelium in COPD is dependent on differentiation and confined to subsets of cells

### **Authors**

Mohamad N. Ali, Michiko Mori, Tinne C.J. Mertens, Premkumar Siddhuraj, Jonas S. Erjefält, Patrik Önerfjord, Pieter S. Hiemstra, Arne Egesten

**Figure S1. Phenotypic characterization of OPN-expressing cells in small airways of a never smoking controls**

Immunofluorescence was used to detect possible co-localization of OPN and mucin 5AC (MUC5AC) in goblet cells (**A**), uteroglobin (UTG) in club cells (**B**), p63 in basal cells (**C**), and forkhead box protein J1 (FOXJ1) in ciliated cells (**D**). In the overlay, a high degree of co-localization was observed for OPN and MUC5AC in goblet cells and UTG in club cells. One representative donor out of three. Scale bars = 100  $\mu$ m.



**Table S1. Subject characteristics**

Characteristic	Never-smokers	Smokers w/o COPD	GOLD I COPD	GOLD II-III* COPD	GOLD IV COPD
Subjects, n	8	6	6	12	9
Gender, male/female	2/6	2/4	4/2	9/3	4/5
Age, years	66 (33-76)#	57 (47-68)	68 (56-75)	66 (53-77)	62 (53-66)
Smoking history, pack-years	0	36 (20-80)	39 (25-66)	46 (30-65)	40 (25-60)
Smoking status, ex-smokers/current	NA	2/4	3/3	7/5	10/0
FEV <sub>1</sub>	2.5 (1.7-5.1)	2.8 (1.9-3.5)	2.9 (1.6-3.2)	1.8 (1.2-2.9)	0.6 (0.4-1.0) □ □
FEV <sub>1</sub> , % of predicted	109 (82-141)	95 (82-120)	86 (80-95)	67 (43-78)	24 (15-27) □ □ □
FEV <sub>1</sub> /(F)VC, %	82 (66-121)	76 (71-88)	67 (65-70)	61 (41-68)	32 (20-39)
Inhaled β <sub>2</sub> -agonists					
Short-acting (yes/no/unknown)	0/8/0	0/6/0	1/5/0	2/10/0	4/4/1‡
Long-acting (yes/no/unknown)	0/8/0	0/6/0	0/6/0	0/12/0	3/5/1‡
Inhaled anticholinergics					
Short-acting (yes/no/unknown)	0/8/0	0/6/0	1/5/0	2/10/0	2/6/1‡
Long-acting (yes/no/unknown)	0/8/0	0/6/0	0/6/0	0/12/0	5/3/1‡
Inhaled short-acting β <sub>2</sub> -agonist plus anticholinergics (yes/no/unknown)	0/8/0	0/6/0	0/6/0	0/12/0	3/5/1‡
Corticosteroids					
Inhaled (yes/no/unknown)	0/8/0	0/6/0	0/6/0	1/11/0	2/6/1‡
Oral (yes/no/unknown)	0/8/0	0/6/0	0/6/0	0/12/0	2/6/1‡
Inhaled long-acting β <sub>2</sub> -agonist plus corticosteroids (yes/no/unknown)	0/8/0	0/6/0	0/6/0	1/11/0	6/2/1‡
Mucolytics (yes/no/unknown)	0/8/0	0/6/0	2/4/0	0/12/0	5/3/1‡

*Definition of abbreviations:* COPD = chronic obstructive pulmonary disease; FEV<sub>1</sub> = forced expiratory volume in one second; (F)VC = (forced) vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease.

Values are median (range) or n.

\* Two patients with GOLD Stage III COPD (median value of FEV<sub>1</sub>% of predicted, 44.5%; range 43.2-45.9).

# The mean value of the study group is 63 years.

‡ One patient with unknown medical history.

**Table S2. Primer sequences**

<i>Gene</i>	<b>Forward Primer</b>	<b>Reverse Primer</b>
<i>OPN</i>	5'-GGACTCCATTGACTCGAACGACTCTG-3'	5'-AACCACACTATCACCTCGGCCATC-3'
<i>FOXJ1</i>	5'-GGAGGGGACGTAATCCCTA-3'	5'-TTGGTCCCAGTAGTTCCAGC-3'
<i>MUC5AC</i>	5'-ATTTTTTCCCCACTCCTGATG-3'	5'-AAGACAACCCACTCCCAACC-3'
<i>p63</i>	5'-CCACCTGGACGTATTCCACTG-3'	5'-TCGAATCAAATGACTAGGAGGGG-3'
<i>UTG</i>	5'-CCCTGGTCACACTGGCTCTCTGC-3'	5'-CCCCTGCCTCCCTCATGTCTTG-3'
<i>RPL13A</i>	5'-AAGGTGGTGGTCGTACGCTGTG-3'	5'-CGGGAAGGGTTGGTGTTCATCC-3'

OPN, osteopontin; FOXJ1, forkhead box protein J1; MUC5AC, mucin 5AC; p63, tumor protein p63; UTG, uteroglobin; RPL13A, ribosomal protein L13A.